Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)

Nicole McCarthy; Frances Boyle; Nicholas Zdenkowski; James Bull; Eugene Leong; Andrew Simpson; George Kannourakis; Prudence Francis; Jacquie Chirgwin; Ehtesham Abdi; Val Gebski; Anne-Sophie Veillard; Diana Zannino; Nicholas Wilcken; Linda Reaby; Dianne F Lindsay; Heath D Badger; John F Forbes

doi:10.1016/j.breast.2013.12.001

Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)

Nicole McCarthy, Frances Boyle, Nicholas Zdenkowski, James Bull, Eugene Leong, Andrew Simpson, George Kannourakis, Prudence Francis, Jacquie Chirgwin, Ehtesham Abdi, Val Gebski, Anne-Sophie Veillard, Diana Zannino, Nicholas Wilcken, Linda Reaby, Dianne F Lindsay, Heath D Badger, John F Forbes

Eastern Health Clinical School

Research output: Contribution to journal › Article › Research › peer-review

6 Citations (Scopus)

Abstract

Neoadjuvant chemotherapy has a sound rationale for use in women with large operable breast cancer, and achievement of pathological complete response (pCR) is prognostic. Epirubicin and cyclophosphamide followed by docetaxel is a standard chemotherapy regimen for early breast cancer. Inmetastatic breast cancer the combination of gemcitabine and a taxane has shown promising results. This phase II study investigated the efficacy and safety of incorporating gemcitabine into neoadjuvant therapy.

Original language	English
Pages (from-to)	142 - 151
Number of pages	10
Journal	The Breast
Volume	23
Issue number	2
DOIs	https://doi.org/10.1016/j.breast.2013.12.001
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.breast.2013.12.001

Cite this

McCarthy, N., Boyle, F., Zdenkowski, N., Bull, J., Leong, E., Simpson, A., Kannourakis, G., Francis, P., Chirgwin, J., Abdi, E., Gebski, V., Veillard, A.-S., Zannino, D., Wilcken, N., Reaby, L., Lindsay, D. F., Badger, H. D., & Forbes, J. F. (2014). Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem). The Breast, 23(2), 142 - 151. https://doi.org/10.1016/j.breast.2013.12.001

@article{eac6255c7410409fa1ee01c01e84f599,

title = "Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)",

abstract = "Neoadjuvant chemotherapy has a sound rationale for use in women with large operable breast cancer, and achievement of pathological complete response (pCR) is prognostic. Epirubicin and cyclophosphamide followed by docetaxel is a standard chemotherapy regimen for early breast cancer. Inmetastatic breast cancer the combination of gemcitabine and a taxane has shown promising results. This phase II study investigated the efficacy and safety of incorporating gemcitabine into neoadjuvant therapy.",

author = "Nicole McCarthy and Frances Boyle and Nicholas Zdenkowski and James Bull and Eugene Leong and Andrew Simpson and George Kannourakis and Prudence Francis and Jacquie Chirgwin and Ehtesham Abdi and Val Gebski and Anne-Sophie Veillard and Diana Zannino and Nicholas Wilcken and Linda Reaby and Lindsay, {Dianne F} and Badger, {Heath D} and Forbes, {John F}",

year = "2014",

doi = "10.1016/j.breast.2013.12.001",

language = "English",

volume = "23",

pages = "142 -- 151",

journal = "The Breast",

issn = "0960-9776",

publisher = "Churchill Livingstone",

number = "2",

}

McCarthy, N, Boyle, F, Zdenkowski, N, Bull, J, Leong, E, Simpson, A, Kannourakis, G, Francis, P, Chirgwin, J, Abdi, E, Gebski, V, Veillard, A-S, Zannino, D, Wilcken, N, Reaby, L, Lindsay, DF, Badger, HD & Forbes, JF 2014, 'Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)', The Breast, vol. 23, no. 2, pp. 142 - 151. https://doi.org/10.1016/j.breast.2013.12.001

TY - JOUR

T1 - Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)

AU - McCarthy, Nicole

AU - Boyle, Frances

AU - Zdenkowski, Nicholas

AU - Bull, James

AU - Leong, Eugene

AU - Simpson, Andrew

AU - Kannourakis, George

AU - Francis, Prudence

AU - Chirgwin, Jacquie

AU - Abdi, Ehtesham

AU - Gebski, Val

AU - Veillard, Anne-Sophie

AU - Zannino, Diana

AU - Wilcken, Nicholas

AU - Reaby, Linda

AU - Lindsay, Dianne F

AU - Badger, Heath D

AU - Forbes, John F

PY - 2014

Y1 - 2014

N2 - Neoadjuvant chemotherapy has a sound rationale for use in women with large operable breast cancer, and achievement of pathological complete response (pCR) is prognostic. Epirubicin and cyclophosphamide followed by docetaxel is a standard chemotherapy regimen for early breast cancer. Inmetastatic breast cancer the combination of gemcitabine and a taxane has shown promising results. This phase II study investigated the efficacy and safety of incorporating gemcitabine into neoadjuvant therapy.

AB - Neoadjuvant chemotherapy has a sound rationale for use in women with large operable breast cancer, and achievement of pathological complete response (pCR) is prognostic. Epirubicin and cyclophosphamide followed by docetaxel is a standard chemotherapy regimen for early breast cancer. Inmetastatic breast cancer the combination of gemcitabine and a taxane has shown promising results. This phase II study investigated the efficacy and safety of incorporating gemcitabine into neoadjuvant therapy.

UR - http://www.sciencedirect.com/science/article/pii/S0960977613003135

U2 - 10.1016/j.breast.2013.12.001

DO - 10.1016/j.breast.2013.12.001

M3 - Article

SN - 0960-9776

VL - 23

SP - 142

EP - 151

JO - The Breast

JF - The Breast

IS - 2

ER -

Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)

Abstract

UN SDGs

Access to Document

Other files and links

Cite this